Comparing clinical outcomes between patients with urothelial carcinoma who treated neoadjuvant chemotherapy by gemcitabine-cisplatin and dose dense MVAC.

被引：0
|
作者：
Lee, Yongjune
Kim, Young Seok
Hong, Bumsik
Cho, Yong Mee
Lee, Jae-Lyun
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea
[5] Asan Med Ctr, Seoul, South Korea
[6] Univ Ulsan, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.376
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
376
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC
    Lee, Yongjune
    Kim, Young Seok
    Hong, Bumsik
    Cho, Yong Mee
    Lee, Jae-Lyun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (11) : 3421 - 3429
  • [2] GEMCITABINE-CISPLATIN VERSUS MVAC CHEMOTHERAPY IN UROTHELIAL CARCINOMA: A NATIONWIDE COHORT STUDY
    Choi, Se Young
    Tae, Jong Hyun
    Chi, Byung Hoon
    Chang, In Ho
    Kim, Tae-Hyoung
    Myung, Soon Chul
    Kim, Jung Hoon
    Kim, Jin Wook
    Lee, Yong Seong
    JOURNAL OF UROLOGY, 2023, 209 : E441 - E441
  • [3] Gemcitabine-cisplatin versus MVAC chemotherapy in urothelial carcinoma: A nationwide cohort study
    Choi, S. Y.
    Tae, J. H.
    Chi, B. H.
    Chang, I. H.
    Kim, T. -H
    Myung, S. C.
    Kim, J. H.
    Lee, Y. S.
    Kim, J. W.
    EUROPEAN UROLOGY, 2023, 83 : S784 - S785
  • [4] Gemcitabine-cisplatin versus MVAC chemotherapy for urothelial carcinoma: a nationwide cohort study
    Lee, Yong Seong
    Ha, Moon Soo
    Tae, Jong Hyun
    Chang, In Ho
    Kim, Tae-Hyoung
    Myung, Soon Chul
    Nguyen, Tuan Thanh
    Kim, Myoungsuk
    Lee, Kyung-Eun
    Kim, Yuwon
    Woo, Hyun-ki
    Kyoung, Dae-Sung
    Kim, Hasung
    Choi, Se Young
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [5] Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine–cisplatin and high dose-intensity MVAC
    Yongjune Lee
    Young Seok Kim
    Bumsik Hong
    Yong Mee Cho
    Jae-Lyun Lee
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 3421 - 3429
  • [6] Impact of relative dose intensity in gemcitabine-cisplatin chemotherapy for metastatic urothelial carcinoma
    Kohei, Naoki
    Sugiyama, Kyohei
    Chihara, Ichiro
    Muro, Yusuke
    Imamura, Masaaki
    Nishio, Yasunori
    Yoshimura, Koji
    SAGE OPEN MEDICINE, 2018, 6
  • [7] Pathologic response rates between gemcitabine-cisplatin (GC) and methotrexate, vinblastine, doxorubicin hydrochloride, and cisplatin (MVAC) neoadjuvant chemotherapy in muscle-invasive urothelial cell carcinoma of the bladder
    Wright, Jonathan Lawrence
    Lee, Franklin
    Harris, William Proctor
    Cheng, Heather H.
    Zhao, Song
    Champion, Thomas
    Gore, John L.
    Dean, James
    Porter, Michael P.
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [8] Prevalence of atypical urine cytology in patients treated with gemcitabine-cisplatin (GC) for urothelial carcinoma (UC)
    Kruczek, Kimberly R.
    Wang, Lu
    Barkan, Guliz
    Henry, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [9] Optimizing chemotherapy in patients with metastatic transitional-cell carcinoma: High rate of complete response with two sequential dose-dense regimens of cisplatin, gemcitabine, paclitaxel, followed by MVAC.
    Passalacqua, Rodolfo
    Giganti, Maria Olga
    Brighenti, Matteo
    Perrucci, Bruno
    Donini, Maddalena
    Negri, Federica
    Tomasello, Gianluca
    Toppo, Laura
    Liguigli, Wanda
    Poli, Rossana
    Ratti, Margherita
    Benecchi, Luigi
    Prati, Andrea
    Arnaudi, Roberto
    Potenzoni, Michele
    Panni, Stefano
    Lazzarelli, Silvia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [10] Resource utilization analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC)
    Montazeri, Kamaneh
    Dranitsaris, George
    Curran, Catherine
    Thomas, Jonathan David
    Ingham, Matthew D.
    Preston, Mark A.
    Steele, Graeme S.
    Kilbridge, Kerry L.
    Wei, Xiao X.
    McGregor, Bradley Alexander
    Mossanen, Matthew
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345